- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01225419
Mobilization by Plerixafor of Haematopoietic Stem Cells in Children (MEP1)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The extensive chemotherapy followed of hematopoietic stem cells reinjection (HSC) is one therapeutic option which the profit is well demonstrated in the treatment of children's solid tumors. It's one of the "standard" treatment of the following tumors: neuroblastoma, metastatic medulloblastoma, Ewing sarcoma, lymphoma in relapse; and because of the big chemosensibility of paediatric cancers, stays an important therapeutic option in the rhabdomyosarcoma in relapse or metastatic, nephroblastoma, etc. The stem cells can be taken in the blood by cytapheresis after mobilization with pharmacologic molecules. At present, the reference of the mobilization treatment is the G-CSF (Granulocyte colony-stimulating factor) in monotherapy during 4 to 6 days. His inconveniences are: lasted of the treatment (4 to 6 days), reproduction of the injections (1 to 2 subcutaneous injections daily), day variability of the peak of mobilization, this hematopoietic stimulation imposes to delay the chemotherapy. The plerixafor activates a massive and fast mobilization of the HSC ( hematopoietic stem cells)(between 6 and 11 hours after the injection). Currently, it's indicated in association with the G-CSF ( Granulocyte colony-stimulating factor)in case of mobilization failure. However, his big flexibility of use could be of a big interest in monotherapy at the child. To date, there is in our knowledge no data on the use of this molecule at the child.
Schema of study: Subcutaneous injection of 240 µg/kg of Plerixafor (Mozobil ®, Genzyme) at 8 am the day of the cytapheresis. Determination of CD34+ cells circulating in h0 then every hour of h3 to h11. Taking by cytapheresis from the 5th hour of the injection if the rate of CD34+ is upper or equal in 10.106/l. If the rate of CD34+ in the blood does not reach 10.106/l after the first injection of plerixafor or if the first cytapheresis does not allow the collection of at least 5.106/kg CD34+ cells, the patient will be considered in failure and a conventional mobilization by G-CSF(Granulocyte colony-stimulating factor) will be programmed.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Clermont-Ferrand, France, 63003
- Chu Clermont-Ferrand
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- 0 to 18 years old
- Solid malign tumor
- Lansky score ≥ 70%
- Indication of hematopoietic stem cell taking by cytapheresis for extensive chemotherapy followed by one or several reinjections of hematopoietic stem cells
Exclusion Criteria:
- Administration of hematopoietic growth factors in 8 days preceding the injection of Plerixafor.
- Contraindication in the cytapheresis or in the extensive chemotherapy.
- Clinical or biological state dissuading the realization of the cytapheresis
- Chemotherapy in 15 days preceding the injection of plerixafor or neutrophils < 1500/mm3
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Percentage of the children to whom 5.106 cells CD34 + / kg can be collected in 2 masses blood treated (one cytapheresis).
Time Frame: between H4 and H9 at day 0
|
between H4 and H9 at day 0
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Describe the kinetics of mobilization of the hematopoietic progenitor at the child in situation of hematopoietic stable state after a subcutaneous injection of plerixafor
Time Frame: between the injection and the apheresis at day 0
|
between the injection and the apheresis at day 0
|
Describe the pharmacokinetics of the plerixafor at the child
Time Frame: between the injection and the apheresis at day 0
|
between the injection and the apheresis at day 0
|
Describe the side effects
Time Frame: day 0 to day 3
|
day 0 to day 3
|
Describe the capacity of hematopoietic reconstruction of taken cells after mobilization by plerixafor only
Time Frame: during the 30 following days
|
during the 30 following days
|
the toxicity of the plerixafor at the child.
Time Frame: day 0 to day 3
|
day 0 to day 3
|
Collaborators and Investigators
Investigators
- Principal Investigator: Etienne MERLIN, University Hospital, Clermont-Ferrand
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CHU-0082
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Children Cancer, Solid Tumor
-
Gustave Roussy, Cancer Campus, Grand ParisUnknown
-
Institut CurieCompletedMetastatic and/or High Risk Solid Tumor of ChildrenFrance
-
Albert Einstein College of MedicineTerminatedCancer | Solid Tumor | Metastatic Solid Tumor | Metastatic dMMR Solid CancerUnited States
-
Shenzhen Ionova Life Sciences Co., Ltd.Merck Sharp & Dohme LLCRecruitingCancer | Solid Tumor, Adult | Solid Carcinoma | Solid Tumor, Unspecified, Adult | Cancer Metastatic | Tumor, SolidUnited States
-
Novartis PharmaceuticalsTerminatedCancer | Solid Tumor | Advanced Solid TumorJapan
-
Spago Nanomedical ABRecruitingSolid Tumor | Metastatic Cancer | Refractory Cancer | Locally Advanced Solid Tumor | Unresectable Solid Tumor | Recurrent Solid TumorAustralia
-
Invitae CorporationRecruitingCancer | Solid Tumor | Solid Tumor, AdultUnited States
-
Daiichi Sankyo Co., Ltd.RecruitingSolid Tumor | Metastatic Solid Tumor | Advanced CancerJapan, United States, Canada
-
Sairopa B.V.RecruitingMetastatic Solid Tumor | Solid Tumor, Adult | Refractory CancerUnited States, Moldova, Republic of
-
Panolos BioscienceRecruitingMetastatic Colorectal Cancer | Hepatocellular Carcinoma | Gastric Cancer | Solid Tumor | Advanced Solid Tumor | Solid Tumor, AdultKorea, Republic of
Clinical Trials on Plerixafor, mozobil
-
National Heart, Lung, and Blood Institute (NHLBI)Completed
-
Stephen CoubanGenzyme, a Sanofi CompanyCompletedMalignant Lymphoma, Stem Cell TypeCanada
-
University Health Network, TorontoPrincess Margaret Hospital, CanadaCompletedAcute Myeloid LeukemiaCanada
-
University of WashingtonCompleted
-
Genzyme, a Sanofi CompanyCompleted
-
Genzyme, a Sanofi CompanyCompletedRenal ImpairmentUnited States
-
Fondazione IRCCS Istituto Nazionale dei Tumori,...Completed
-
Hospital Universitario Dr. Jose E. GonzalezUnknownLymphoma, Non-Hodgkin | Myeloma | Lymphoma, Hodgkin | Stem Cell Transplant ComplicationsMexico
-
Genzyme, a Sanofi CompanyCompletedLymphoma, Non-Hodgkin | Multiple MyelomaUnited States
-
Genzyme, a Sanofi CompanyAnorMEDCompletedLymphoma, Non-Hodgkin | Multiple MyelomaGermany